InObvious VenturesbyNan Li·Aug 3, 2021Investing in Iterative ScopesBringing personalized medicine to gastroenterology
InObvious VenturesbyNan Li·Apr 16, 2021To RXRX and BeyondTheir IPO is another milestone along a longer journey for Recursion.
InObvious VenturesbyNan Li·Mar 8, 2021Promoting Meera Clark to PrincipalLeveling up the Obvious Investment TeamA response icon4A response icon4
InObvious VenturesbyNan Li·Jul 21, 2020Investing in DexterityFreeing robots from cages, and pioneering the next generation of industrial roboticsA response icon1A response icon1
InObvious VenturesbyNan Li·Feb 4, 2020Investing in Inato95% of the eligible patients for a clinical trial are never considered. It’s time for a transformation.
InWorld PositivebyNan Li·Oct 29, 2019The New BiologyA counterintuitive approach to biological design challenges
InObvious VenturesbyNan Li·Oct 23, 2019Investing in LabGeniusAdvancing protein therapies using computational biology
InWorld PositivebyNan Li·Apr 30, 2019Industrial IQ: Where High Tech Meets Low TechTech is breaking out of the Silicon Valley sandbox, transforming traditional, trillion-dollar industries in the process.A response icon1A response icon1
InObvious VenturesbyNan Li·Sep 25, 2018Our Investment in DarwinAIDriving towards a safe, high performance future for AI
InObvious VenturesbyNan Li·Jul 17, 2018Welcome Will Dzierson!Designer in Residence at Obvious Ventures
